New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2013
05:55 EDTSHPG, SHPG, SHPG, SHPG, SHPG, SQNM, SQNM, SQNM, SQNM, SQNM, RHHBY, RHHBY, RHHBY, RHHBY, RHHBY, PFE, PFE, PFE, PFE, PFE, PKI, PKI, PKI, PKI, PKI, LMNX, LMNX, LMNX, LMNX, LMNX, ILMN, ILMN, ILMN, ILMN, ILMN, HOLX, HOLX, HOLX, HOLX, HOLX, FLDM, FLDM, FLDM, FLDM, FLDM, GOLD, GOLD, GOLD, GOLD, GOLD, ATHN, ATHN, ATHN, ATHN, ATHN, ALXN, ALXN, ALXN, ALXN, ALXN, AFFY, AFFY, AFFY, AFFY, AFFY, A, A, A, A, AAmerican College of Medical Genetics & Genomics to hold annual meeting
ACMG Annual Clinical Genetics Meeting 2013 is being held in Phoenix, Arizona on March 19-23.
News For A;AFFY;ALXN;ATHN;GOLD;FLDM;HOLX;ILMN;LMNX;PKI;PFE;RHHBY;SQNM;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 26, 2015
09:20 EDTFLDMFluidigm has negative read through from Becton Dickinson deal, says Leerink
Subscribe for More Information
08:33 EDTLMNXLuminex submits 510(k) application for the NxTAG respiratory pathogen panel
Luminex has submitted a 510(k) application to the FDA for the company's NxTAG Respiratory Pathogen Panel, a respiratory assay that will enable laboratories to simultaneously detect 21 respiratory pathogens in a single closed tube system in a format that scales to changes in throughput requirements and responds to seasonal changes in demand.
07:32 EDTPFEPfizer launches Phase 3 trial of targeted therapy for breast cancer patients
Subscribe for More Information
07:28 EDTILMNIllumina added to Focus List at Citi
Subscribe for More Information
06:16 EDTPFEAlvogen to acquire product portfolio from Pfizer for US market
Subscribe for More Information
August 25, 2015
17:32 EDTSQNMSequenom enters collaboration with UC San Diego Moores Cancer Center
Subscribe for More Information
16:43 EDTSHPGOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
14:16 EDTPFEMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
09:03 EDTSHPGAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
07:06 EDTSHPGShire reaches CINRYZE agreement with Sanquin Blood Supply
Subscribe for More Information
05:09 EDTILMNIllumina enters oncology collaboration with Burning Rock
Subscribe for More Information
August 24, 2015
18:55 EDTSHPGOn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTSHPGJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
12:57 EDTPFEFTC requires Pfizer to sell rights to four products as condition of buying Hospira
Subscribe for More Information
12:01 EDTRHHBYRoche buys nucleic acid purification technology from Lumora
Roche has signed a definitive asset purchase agreement with Lumora for products associated with the patent-protected Heat Elution technology for nucleic acid purification of multiple sample types including challenging formalin-fixed paraffin-embedded tumor samples. Roche plans to explore integrating this technology into its sequencing workflow solution.
08:29 EDTILMN, SQNMWilliam Blair to hold a field trip
Subscribe for More Information
08:16 EDTPFEBristol-Myers, Pfizer to present new data on Eliquis at ESC Congress 2015
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation and venous thromboembolism patient populations. In addition, data from the AEGEAN study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
08:01 EDTPFEPfizer receives clearance from FTC for Hospira acquisition
Subscribe for More Information
07:02 EDTGOLDRandgold upgraded to Outperform from Sector Perform at RBC Capital
Subscribe for More Information
August 23, 2015
12:35 EDTPFE, RHHBYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use